Tandem Diabetes Care (TNDM) Net Income Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 343.24% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 2.38% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 45.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.19% |
| Dec 31, 2025 | 67.52% |
| Sep 30, 2025 | 24.42% |
| Jun 30, 2025 | -51.59% |
| Mar 31, 2025 | -107.09% |
| Dec 31, 2024 | -58.51% |
| Sep 30, 2024 | -82.10% |
| Jun 30, 2024 | -113.18% |
| Mar 31, 2024 | -103.62% |
| Dec 31, 2023 | -55.57% |
| Sep 30, 2023 | -51.79% |
| Jun 30, 2023 | -6.94% |
| Mar 31, 2023 | -102.72% |
| Dec 31, 2022 | -99.81% |
| Sep 30, 2022 | -156.52% |
| Jun 30, 2022 | -115.11% |
| Mar 31, 2022 | 13.85% |
| Dec 31, 2021 | 42.91% |
| Sep 30, 2021 | 29.42% |
| Jun 30, 2021 | 31.86% |
| Mar 31, 2021 | 30.98% |
| Dec 31, 2020 | 55.85% |
| Sep 30, 2020 | 10.46% |
| Jun 30, 2020 | -15.58% |
| Mar 31, 2020 | 11.11% |
| Dec 31, 2019 | 30.04% |
| Sep 30, 2019 | 53.24% |
| Jun 30, 2019 | 55.32% |
| Mar 31, 2019 | -6.34% |
| Dec 31, 2018 | 32.60% |
| Sep 30, 2018 | -22.53% |
| Jun 30, 2018 | 9.71% |
| Mar 31, 2018 | 8.83% |
| Dec 31, 2017 | 18.31% |
| Sep 30, 2017 | 11.61% |
| Jun 30, 2017 | -1.12% |
| Mar 31, 2017 | -0.55% |
| Dec 31, 2016 | 6.83% |
| Sep 30, 2016 | -32.77% |
| Jun 30, 2016 | -7.41% |
| Mar 31, 2016 | -38.70% |